Argent Advisors’s Blueprint Medicines BPMC Stock Holding History

Argent Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-80	Closed	-$6K	–	171
2019 Q4	$6K	Buy	+80	New	+$5.99K	﹤0.01%	350

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Argent Advisors's BPMC Position: Q1 2020 in Review

Argent Advisors sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 80 shares — an estimated $6K sold.

Argent Advisors first reported a position in BPMC in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

Argent Advisors reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
Argent Advisors sold 80 Blueprint Medicines shares in Q1 2020, an estimated $6K.
Argent Advisors first reported a position in Blueprint Medicines in Q4 2019 and held it in 1 quarter.
Argent Advisors's Blueprint Medicines position peaked at $6K in Q4 2019.
213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Argent Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.